论文部分内容阅读
目的采用超声造影(CEUS)新技术诊断肝细胞性肝癌(HCC),与对比增强CT(CECT)比较其增强表现,评估CEUS的临床应用价值。方法98个HCC病灶接受了CEUS和CECT检查。CEUS造影剂为声诺维,对比脉冲序列(CPS)成像技术。CECT造影剂为优维显,常规双期增强扫描。结果98个(100%)病灶在CEUS和CECT动脉期均显示增强,表现为高增强分别为98个(100%)和94个(95.9%,P=0.121),CECT4个(4.1%)病灶表现为等增强。在门脉期,CEUS和CECT显示病灶消退至低增强分别为82个(83.7%)和83个(84.7%),P=0.845。CEUS和CECT显示肿瘤周边薄环状增强的病灶数目分别为30个(30.6%)和31个(31.6%,P=0.877),显示瘤内血管的病灶数目分别为94个(95.9%)和36个(36.7%,P=0.000)。结论HCC的CEUS增强表现与CECT一致,为临床提供了一种简便易行的HCC定性诊断手段。
Objective To evaluate the clinical value of CEUS in diagnosis of hepatocellular carcinoma (HCC) by contrast-enhanced ultrasound (CEUS) and contrast-enhanced CT (CECT). Methods 98 HCC lesions underwent CEUS and CECT examinations. The CEUS contrast agent is SonoVision, a contrast pulse-sequence (CPS) imaging technique. CECT contrast agent for the excellent Victoria significant conventional double-phase enhanced scan. Results 98 (100%) lesions showed enhancement in the CEUS and CECT arterial phases with high enhancement of 98 (100%) and 94 (95.9%, P = 0.121) and 4 (4.1%) CECT lesions, respectively For such enhancements. In the portal phase, CEUS and CECT showed a regression of lesions to low enhancement of 82 (83.7%) and 83 (84.7%), respectively, with P = 0.845. CEUS and CECT showed that there were 30 (30.6%) and 31 (31.6%, P = 0.877), respectively, lesions with enhanced lesion around the tumor, showing 94 (95.9%) lesions and 36 Months (36.7%, P = 0.000). Conclusions CEUS enhanced performance of HCC is consistent with that of CECT, which provides a simple and convenient diagnostic method for HCC in clinic.